drugset
drugset / Trial / NCT05830123

ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas

NCT05830123 ↗

Phase 2 Recruiting 170 enrolled Hansoh BioMedical R&D Company
RandomizedParallel-groupOpen-labelTreatment

Summary

HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. This is a phase 2, open-label, multi-center study to evaluate the efficacy, safety, pharmacokinetics (PK) and immunogenicity of HS-20093 as a monotherapy in patients with relapsed or refractory osteosarcoma and other sarcomas.

Timeline

Start
2023-06-08
Primary completion
2025-12-31
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject HS-20093 Other / unclassified 8 mg/kg Intravenous
Subject HS-20093 Other / unclassified 12 mg/kg Intravenous

Indications

osteosarcoma